Today: 20 May 2026
DBS share price ticks up as Singapore bank rally rolls on; what to watch next
23 January 2026
2 mins read

DBS share price ticks up as Singapore bank rally rolls on; what to watch next

SINGAPORE, Jan 23, 2026, 15:01 SGT — Regular session

  • DBS shares rose about 1% in afternoon trading, mirroring gains in Singapore’s leading banks.
  • Analysts are turning more bullish on UOB and OCBC, while DBS is seen as having limited upside.
  • Focus shifts to next week’s policy signals and DBS’ full-year earnings report set for Feb. 9.

DBS Group Holdings Ltd shares edged up 1.15% on Friday, closing at S$58.75 on a delayed quote. The stock fluctuated between S$57.90 and S$58.83 throughout the session, fueled by renewed interest in Singapore bank stocks.

These changes matter because major banks dominate Singapore’s benchmark, often steering the whole market. Investors are watching interest rate trends closely, given their direct effect on bank profits through the net interest margin — the gap between what banks earn on loans and pay on deposits.

A sharp move into the sector has traders rethinking the pecking order among the three. The market’s focus isn’t solely on which banks benefit from high rates anymore; it’s shifted to who can defend fees, keep credit costs steady, and still produce cash returns.

Friday’s action was led by rivals UOB and OCBC. UOB jumped as much as 4.8%, with OCBC climbing up to 3.4%, pushing the Straits Times Index to fresh record levels, the Business Times reported. Jayden Vantarakis from Macquarie pointed to Singapore’s standing as a “safe-haven” pulling in wealth flows. Kathy Chan of Morningstar added that the banks—“especially UOB”—were “catching up” after trailing DBS. The Business Times

Some analysts remain cautious despite DBS’s steady rise. Macquarie Capital assigned an “underperform” rating to the stock, setting a S$50 target price, the Straits Times reported. The firm highlighted “the least room for DBS to surprise” relative to estimates. It also pointed to risks tied to Hong Kong’s commercial property market and a dimmer sector earnings outlook in 2026. The Straits Times

DBS has flagged a capital-markets move that’s more likely to be noted than acted on by investors. The bank intends to redeem an A$300 million floating-rate subordinated note due 2031, with the redemption set for April 8, 2026, subject to approval from the Monetary Authority of Singapore. This was detailed in a notice reported by S&P Capital IQ. These subordinated notes rank below senior debt in a wind-down and typically count as regulatory capital.

Friday brought a shift in the macro outlook after fresh inflation data. Singapore’s core inflation rose 1.2% year-on-year in December. The Monetary Authority of Singapore plans to update its forecasts in the monetary policy statement due Jan. 29, a joint release from MAS and the trade ministry confirmed.

Global interest rates remain under the spotlight. The U.S. Federal Reserve’s meeting on Jan. 27-28 might shift the timeline for rate cuts, which could ripple through Asian bank stocks.

DBS investors are once again asking: just how quickly will margins tighten, and can fees from wealth management and transactions fill the gap? Credit provisions—reserves set aside for possible loan losses—are still in the spotlight, especially those tied to commercial real estate and exposures connected to China.

DBS plans to unveil its full-year 2025 earnings before the market opens on Monday, Feb. 9, per an SGX announcement. Investors are zeroing in on dividend guidance, margin forecasts, and any shifts in credit-cost assumptions.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week
Previous Story

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week

Sensex dives 800 points as rupee hits record low, foreign selling bites
Next Story

Sensex dives 800 points as rupee hits record low, foreign selling bites

Go toTop